FDA declines approval of Novocure's Optune Mya over uncertain clinical benefit

By Public Technologies
  • The FDA issued Novocure a not approvable letter for Optune Mya, blocking its premarket approval application.
  • The application covers adults with brain metastases from non-small cell lung cancer following stereotactic radiation.
  • Uncertainty over the degree of clinical benefit prevented approval; the FDA raised no safety concerns.
  • Novocure plans to meet with the FDA to explore potential approval options without additional clinical studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611090700BIZWIRE_USPR_____20261109_BW483647) on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.